Home
0086-571-8627 3270
service@chemball.com
Sign In
Please enter your email address correctly
Please enter your password
Forgot Password
OR
Join Free >
Dapagliflozin
CAS NO.: 461432-26-8
FOB Price: NEGOTIABLE Get Latest Price
Specification: ≥99.0%
Documentation: Get COA after inquiry
Lead Time: 14-30 days
Max Capacity: -
Packing: 25KG/Fibre Drum
Product Detail
Properties

Dapagliflozin

Introduction:

Dapagliflozin is a sodium glucose co transporter 2 inhibitor, which can be used as an important choice in the treatment of diabetes mellitus. It can be used as an assistant diet and exercise to improve blood glucose control in adults with type 2 diabetes.

CAS:461432-26-8

Molecular formula: C21H25ClO6

Molecular weight: 408.88

Structural type:

Product Application:

Dapagliflozin works by inhibiting sodium glucose transporter 2 (SGLT2), a protein in the kidney that reabsorbs glucose into the blood. This allows excess glucose to be excluded from the body through the urine, thereby improving blood glucose control without increasing insulin secretion. The use of this drug requires normal renal function, and it is forbidden for patients with moderate to severe renal insufficiency. Combined use of metformin, pioglitazone, glimepiride and insulin can significantly reduce HbA1c and fasting blood glucose in patients with type 2 diabetes. The incidence of adverse reactions is similar to that of placebo. Low risk of hypoglycemia can reduce body weight.

Send your message to this supplier
To:
Shandong Chenghuishuangda Pharmaceutical Co.,Ltd.
From:
Please enter your email
Message:
You did not fill in the message!
You can upload 6 files at most
Add Attachment
SEND SUCCESSFUL!
SEND FAILED
Not exactly what you want? One request, multiple quotations Get Quotations Now >>
10YRS
Business Type:
Manufacturing
Country/Region:
Shandong, China
Contacts:
Manager Shen
Position Title:
Sales Manager
Tel:
0086-531-58897055
Visit Factory
Get Free Samples
Less than 1KG required
Please enter the correct email address
Please enter quantity
Please enter remark